Replies to post #765877 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gro,

Thanks for reposting your keen insights 😶

It sounds like you’re spreading rumors and disinformation. I believe you’re referring to Gilead’s Yescarta and your ‘facts’ are a little mixed up…

“As of early 2023, NICE has approved Yescarta (axicabtagene ciloleucel) for routine use in the NHS. After a series of reviews and negotiations, NICE endorsed Yescarta for adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). The approval was based on the evidence of its effectiveness in prolonging survival compared to existing therapies.

This approval marked a shift from earlier hesitations due to concerns about high costs and uncertainty about long-term benefits. The conditional use through the Cancer Drugs Fund helped collect additional evidence, leading to the final NICE endorsement.”

https://pmlive.com/pharma_news/gileads_car-t_cell_therapy_recommended_by_nice_for_lymphoma_1485970/





NICE DCVax-L

[Roman516]

NoGrow, your opinion about the P3 trial statistical guess is worthless as you already know that the real success was the OS data results.
You also know that DCVax should be approved by the MHRA. According to more reputable sources there are no holdups with NWBO at the MHRA, so your fabrication stories once again hold no value, IMO.